# Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis

> **NCT06684522** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Northwestern University** · enrollment: 10 (estimated)

## Conditions studied

- Eyelid Dermatitis

## Interventions

- **DRUG:** Upadacitinib 15 MG

## Key facts

- **NCT ID:** NCT06684522
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06684522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06684522, "Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06684522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*